Perzinfotel

Perzinfotel is a drug that was under development for the treatment of stroke and migraine. It acts as an NMDA antagonist, specifically blocking the glutamate site on the NMDA receptor, which is one of the subtypes of glutamate receptor. This makes it a noncompetitive antagonist.

History

Perzinfotel was developed by the pharmaceutical company Eli Lilly. It reached Phase II clinical trials for the treatment of acute ischemic stroke and migraine, but development was discontinued due to lack of efficacy.

Mechanism of action

Perzinfotel works by blocking the glutamate site on the NMDA receptor, one of the subtypes of glutamate receptor. This makes it a noncompetitive antagonist. The NMDA receptor is a major subtype of glutamate receptor, and it plays a key role in the transmission of electrical signals in the brain. By blocking this receptor, perzinfotel can potentially reduce the damage caused by excessive glutamate release, which is a common feature of many neurological disorders, including stroke and migraine.

Clinical trials

Perzinfotel reached Phase II clinical trials for the treatment of acute ischemic stroke and migraine. However, development was discontinued due to lack of efficacy. In the clinical trials, perzinfotel was found to be safe and well-tolerated, but it did not show significant benefits in reducing the symptoms of stroke or migraine.

See also

• NMDA antagonist
• Glutamate receptor
• Stroke
• Migraine

Perzinfotel Resources
Latest articles Most recent articles Ongoing trials	Wikipedia